Cell-free NGS analysis for solid tumor cancers
NeoLAB® Solid Tumor Liquid Biopsy is an NGS assay for pan-cancer that gives you a comprehensive, single order testing solution for solid tumors. It includes 44 genes involved in solid tumor development and progression, covering actionable markers supported by clinical guidelines and ongoing clinical trials.
NeoLAB® Solid Tumor Liquid Biopsy
Pan-cancer tumor types (bladder, brain/CNS, breast, cervical, colorectal, stomach, head, and neck, etc.)
Detects 900+ hotspot SNVs and indels across 44 genes
Accurate results are returned within 7 calendar days after sample is received
- 98% accuracy, 95.1% sensitivity, 98.8% specificity
- Limit of detection: 0.1% allele fraction for indels; 0.15% for SNV
Identify Targetable Alteration
Monitor Disease Status
Detect Potential Resistance
Genes investigated
| AKT1 | ERBB3 | HRAS | NTRK3 |
| ALK | ESR1 | IDH1 | PDGFRA |
| APC | FBXW7 | IDH2 | PIK3CA |
| AR | FGFR1 | KIT | PTEN |
| ARAF | FGFR2 | KRAS | RAF1 |
| BRAF | FGFR3 | MAP2K1 | RET |
| CHEK2 | FGFR4 | MAP2K2 | ROS1 |
| CTNNB1 | FLT3 | MET | SF3B1 |
| DDR2 | GNA11 | MTOR | SMAD4 |
| EGFR | GNAQ | NRAS | SMO |
| ERBB2 | GNAS | NTRK1 | TP53 |
See complete test details for NeoLAB® Solid Tumor Liquid Biopsy.
Get a printable test description and specimen requirements.
NeoGenomics is proud to offer site location and in-home specimen collection for liquid biopsy assays through our national mobile phlebotomy program, providing sage and convenient blood draws for liquid biopsy with no added costs for patients.
Contact Us To Get Started!
Work with us – your premier oncology partner – to optimize cancer care for patients